- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871778
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD)
November 18, 2021 updated by: Parion Sciences
A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
123
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
Copenhagen, Denmark
-
-
-
-
-
Hannover, Germany
-
Heidelberg, Germany
-
-
North Rhine-Westphalia
-
Munster, North Rhine-Westphalia, Germany
-
-
-
-
-
Pisa, Italy
-
-
-
-
-
Amsterdam, Netherlands
-
Rotterdam, Netherlands
-
-
-
-
-
Rabka-Zdroj, Poland
-
-
-
-
-
Cambridge, United Kingdom
-
London, United Kingdom
-
Southampton, United Kingdom
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
California
-
Palo Alto, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Miami, Florida, United States
-
Tampa, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
-
Kansas
-
Kansas City, Kansas, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Minnesota
-
Minneapolis, Minnesota, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
Saint Louis, Missouri, United States
-
-
New York
-
New York, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Ohio
-
Cleveland, Ohio, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Columbia, South Carolina, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject must have evidence supportive of a PCD diagnosis.
- Subjects with percent predicted FEV1 of ≥40 to <90 percentage points
- Non-smoker for at least 90 days prior to the Screening Visit and less than a 5 pack-year lifetime history of smoking
- Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1
- If currently using daily inhaled HS, must be able to discontinue its use for the duration of the study.
- If taking daily chronic or chronic cycling antibiotics, has been on a consistent regimen for at least 4 months prior to the Screening Visit.
- Clinically stable (as deemed by the investigator) for at least 14 days prior to the Screening Visit
- Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit. Subjects of childbearing potential and who are sexually active must meet the contraception requirements.
Exclusion Criteria:
- Diagnosis of CF based on results of sweat chloride or nasal potential difference (NPD) tests or presence of 2 CF-causing mutations in CFTR gene.
- History of any organ transplantation or lung resection or chest wall surgery.
- Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator
- Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).
- Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic visit and long-acting bronchodilator use the night before the first and last clinic visit of each treatment period.
- Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs
- Symptoms of acute upper or lower respiratory tract infection, acute pulmonary exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus disease within 28 days before Day 1 (topical otic antibiotics allowed).
- History of significant intolerance to inhaled HS
- Pregnant and/or nursing females
- Any clinically significant laboratory abnormalities
- History of chronic B. cepacia complex or M. abscessus or M. avium
- Surgery that required general anesthesia and hospitalization within 3 months of Day 1
Additional Exclusion Criteria for Part B:
- In addition to the exclusion criteria above, subjects who participate in Part B and meet any of the following exclusion criteria will not be eligible to continue into Part B
- Unable to swallow tablets.
- Concomitant use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications (e.g., St. John's Wort), and grapefruit/grapefruit juice.
- Known hypersensitivity to ivacaftor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: VX-371 in Hypertonic Saline (HS), Then HS
Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
|
|
Experimental: Part A: HS, Then VX-371 in HS
Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
|
|
Experimental: Part A: VX-371, Then Placebo
Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
|
|
Experimental: Part A: Placebo, Then VX-371
Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
|
|
Experimental: Part B: VX-371 in HS + Ivacaftor
Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
|
|
Experimental: Part B: HS + Ivacaftor
Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
|
|
Experimental: Part B: VX-371 + Ivacaftor
Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
|
|
Placebo Comparator: Part B: Placebo + Ivacaftor
Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Time Frame: Part A: From first dose of study drug up 84 days
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations.
Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between first dose of study drug and up to 84 days that were absent before treatment or that worsened relative to pretreatment state.
TEAEs included both serious and non-serious TEAEs.
|
Part A: From first dose of study drug up 84 days
|
Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Time Frame: Part B: Day 85 up to 28 days after last dose of study drug (56 days)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations.
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between first dose of study drug and up to up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
TEAEs included both serious and non-serious TEAEs.
|
Part B: Day 85 up to 28 days after last dose of study drug (56 days)
|
Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Time Frame: Part A: Study Baseline, Day 29 of each treatment period
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Part A: Study Baseline, Day 29 of each treatment period
|
Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Time Frame: Study Baseline, Day 29 of Part B
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Study Baseline, Day 29 of Part B
|
Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Time Frame: Part B Baseline, Day 29 of Part B
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
|
Part B Baseline, Day 29 of Part B
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
Time Frame: Study Baseline, Day 29 of Part A
|
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms.
The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults.
All items are scored using a 4-point Likert scale.
Scaled score calculated as: [Sum of scores - (n*1)] / [(n*4) - (n*1)]*100.
Where 'n' is the number of questions in domain.
The total score range is from 0-100, where higher score indicates greater improvement.
Change from study baseline >0 indicated improvement.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Study Baseline, Day 29 of Part A
|
Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
Time Frame: Study Baseline, Day 29 of Part B
|
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms.
The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults.
All items are scored using a 4-point Likert scale.
Scaled score calculated as: [Sum of scores - (n*1)] / [(n*4) - (n*1)]*100.
Where 'n' is the number of questions in domain.
The total score range is from 0-100, where higher score indicates greater improvement.
Change from study baseline >0 indicated improvement.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Study Baseline, Day 29 of Part B
|
Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
Time Frame: Part B Baseline, Day 29 of Part B
|
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms.
The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults.
All items are scored using a 4-point Likert scale.
Scaled score calculated as: [Sum of scores - (n*1)] / [(n*4) - (n*1)]*100.
Where 'n' is the number of questions in domain.
The total score range is from 0-100, where higher score indicates greater improvement.
Change from Part B baseline >0 indicated improvement.
Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
|
Part B Baseline, Day 29 of Part B
|
Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29
Time Frame: Study Baseline, Day 29 of Part A
|
SGRQ measured health-related quality of life among participants with respiratory diseases.
It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts).
Total scores range from 0 to 100.
Higher score reflected worse quality of life.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Study Baseline, Day 29 of Part A
|
Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
Time Frame: Study Baseline, Day 29 of Part B
|
SGRQ measured health-related quality of life among participants with respiratory diseases.
It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts).
Total scores range from 0 to 100.
Higher score reflected worse quality of life.
The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
|
Study Baseline, Day 29 of Part B
|
Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
Time Frame: Part B Baseline, Day 29 of Part B
|
SGRQ measured health-related quality of life among participants with respiratory diseases.
It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts).
Total scores range from 0 to 100.
Higher score reflected worse quality of life.
Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
|
Part B Baseline, Day 29 of Part B
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Karl Donn, Parion Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2016
Primary Completion (Actual)
November 20, 2018
Study Completion (Actual)
November 20, 2018
Study Registration Dates
First Submitted
August 12, 2016
First Submitted That Met QC Criteria
August 12, 2016
First Posted (Estimate)
August 18, 2016
Study Record Updates
Last Update Posted (Actual)
December 16, 2021
Last Update Submitted That Met QC Criteria
November 18, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Movement Disorders
- Abnormalities, Multiple
- Ciliopathies
- Dyskinesias
- Ciliary Motility Disorders
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Chloride Channel Agonists
- Ivacaftor
Other Study ID Numbers
- PS-G202
- 2015-004917-26 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Ciliary Dyskinesia
-
University Hospital MuensterAssistance Publique - Hôpitaux de Paris; University of Pisa; Medical University... and other collaboratorsRecruitingPrimary Ciliary Dyskinesia (PCD)Germany
-
University of Alabama at BirminghamMassachusetts General HospitalRecruitingCovid19 | Sinusitis | Cystic Fibrosis | COPD | PCD - Primary Ciliary DyskinesiaUnited States
-
ReCode TherapeuticsSano Genetics; ReverbaRecruitingPrimary Ciliary DyskinesiaUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPrimary Ciliary DyskinesiaUnited States
-
University of BernUniversity of Southampton; Selbsthilfegruppe Kartagener Syndrom und Primäre... and other collaboratorsRecruiting
-
Beijing Children's HospitalShengjing Hospital; Shanghai Children's Medical Center; Shenzhen Children's Hospital and other collaboratorsNot yet recruitingPrimary Ciliary Dyskinesia
-
Universitaire Ziekenhuizen KU LeuvenRecruitingPrimary Ciliary DyskinesiaBelgium
-
University of LeedsCompletedPrimary Ciliary DyskinesiaUnited Kingdom
-
University of SouthamptonAssistance Publique - Hôpitaux de Paris; Hacettepe University; Universitaire... and other collaboratorsUnknownPrimary Ciliary DyskinesiaUnited Kingdom
-
Aerocrine ABCompletedPCDFrance, United States, Denmark, Germany
Clinical Trials on VX-371 + HS
-
Parion SciencesVertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited Kingdom, United States, France, Ireland
-
Chong Kun Dang PharmaceuticalCompletedType II Diabetes MellitusKorea, Republic of
-
Bio-Medical Research, Ltd.Completed
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed